MedTrace Logo

Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer

NCT01007890 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 134

Last updated 2012-10-05

No results posted yet for this study

Summary

The objective of this study is to develop a biomarker to predict pathological complete response in women treated with neoadjuvant chemotherapy for breast cancer. Such a biomarker would assist physicians in selecting the most effective chemotherapy for the individual patient.

Conditions

Interventions

OTHER

ChemoFX Assay

Test of an algorithm to predict pathologic response in patients treated with neoadjuvant chemotherapy for breast cancer.

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Precision Therapeutics

    lead INDUSTRY

Principal Investigators

  • Darrell Lis, RN, MSN · Precision Therapeutics

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01007890 on ClinicalTrials.gov